Senores Pharma Overhauls Senior Management as CTO Elevated, R&D Head Resigns

Senores Pharmaceuticals Ltd. ( (IN:SENORES) ) has shared an announcement.

Senores Pharmaceuticals Ltd. has reshuffled its senior management, with the board approving the categorization of Chief Technology Officer Jatin Gajjar as Senior Management Personnel, effective March 17, 2026. Gajjar brings over three decades of experience in pharmaceutical technology, manufacturing and complex generics, and is expected to provide strategic leadership across R&D, manufacturing and regulatory affairs.

On the same date, President – Research and Development Manohar Lalge resigned, resulting in his cessation as Senior Management Personnel at the close of business hours. The simultaneous elevation of the CTO and departure of the R&D head signals a shift in the company’s leadership structure around innovation, regulatory alignment and product development, with potential implications for its research priorities and operational focus in complex generics and advanced formulations.

More about Senores Pharmaceuticals Ltd.

Senores Pharmaceuticals Ltd. is an India-based pharmaceutical company focused on pharmaceutical technology, complex formulations and generic drug development. From its base in Ahmedabad, the company emphasizes manufacturing operations, injectable formulations and novel drug delivery technologies, targeting key regulated markets while aligning research, development and regulatory functions with its business goals.

Average Trading Volume: 23,671

Technical Sentiment Signal: Buy

Current Market Cap: 34.28B INR

Learn more about SENORES stock on TipRanks’ Stock Analysis page.